Roflumilast is a drug which acts as a selective, long-acting inhibitor of the enzyme PDE-4. It has anti-inflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such as asthma, and chronic obstructive pulmonary disease (COPD). In June 2010, Daxas was approved in the EU for severe COPD associated with chronic bronchitis.[9] In March 2011, Daliresp gained FDA approval in the US for reducing COPD exacerbations.
Ni, Feng; Li, Jianqi. A new route to Roflumilast via copper-catalyzed hydroxylation. Synthesis. Volume 44. Issue 23. Pages 3598-3602. Journal. (2012).
Xiang, Zuo-juan; Sun, Hong-bin. Synthesis and polymorphic study of roflumilast N-oxide. Zhongguo Yaoke Daxue Xuebao. Volume 43. Issue 6. Pages 492-496. Journal. (2012).
Huang, Huan; Huang, Qingguo; Li, Kai; Huang, Qingyun. Method for preparing roflumilast. Assignee Anhui Qingyun Pharmaceutical Co., Ltd., Peop. Rep. China. CN 109516949. (2019).
Dong, Dandan. Roflumilast anti-inflammatory drug intermediates for inhibiting PDE4 enzyme activity. CN 108117515. (2018).
Chen, Yu; Yang, Taotao; Gong, Tengwen. Process for preparation of high-purity Roflumilast. Assignee Shandong Luoxin Pharmaceutical Group Co., Ltd., Peop. Rep. China. CN 105254559. (2016).
: Lin, Guoliang; Liu, Zhidong; Han, Shuo; Geng, Yuxian; Ma, Yuezhong. Method for preparing roflumilast intermediate. Assignee Beijing Winsunny Pharmaceutical Co., Ltd., Peop. Rep. China. CN 103539671. (2014).
Gavhane, Sachin Baban; Wakade, Sanjay Maruti; Kadam, Suresh Mahadev. Novel process for the preparation of 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy) benzamide. Assignee Glenmark Generics Limited, India. IN 2011MU01345. (2014).
Salaet Ferre, Josep; Marquillas Olondriz, Francisco. A process for the preparation of roflumilast. Assignee Interquim, S.A., Spain. WO 2014060464. (2014).
Chen, Yi-Jing; Pikul, Stanislaw; Kuo, Shen-Chun; Chu, Guo-Dong. Process for preparation of roflumilast. Assignee ScinoPharm (Changshu) Pharmaceutical, Ltd., Peop. Rep. China. WO 2013131484. (2013).
Li, Jianqi; Ni, Feng; Zhu, Haoyang; Su, Wenrou; Wang, Jiajing. Method to prepare 3-cyclopropylmethoxy-4-halobenzoic acid derivatives as intermediates in synthesizing roflumilast. Assignee Shanxi C&Y Pharmaceutical Co., Ltd., Peop. Rep. China; Shanghai Institute of Pharmaceutical Industry. CN 102617339. (2012).
